Synthesis and Biological Evaluation of a New Polymeric Conjugate and Nanocarrier with Osteotropic Properties
Source abstract
Abstract
Bone-seeking (osteotropic) drug delivery systems (ODDS) represent an interesting solution for targeting different types of drugs to the bones. In particular, anticancer and antibacterial agents could take advantage of such therapeutic strategy. We have recently developed an innovative approach to this aim: a new osteotropic biomaterial was prepared, based on the conjugation of a poly(lactide-co-glycolide) (PLGA) with the bisphosphonate drug alendronate (PLGA-ALE); its hemo- and cytocompatibility were verified. Starting with this copolymer, an osteotropic nanoparticle system (NP) was produced for the targeted delivery of antineoplastic drugs to osteolytic bone metastases; in particular, doxorubicin was tested as a model drug. The in vitro and in vivo results of the new ODDS are validated in this article. All the experimental data confirmed that the drug retained its activity after loading in the PLGA-ALE NP; they can be thus considered a new promising strategy for active targeting of drugs to bone tissues in different pathological situations.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Radiopharmaceutical Chemistry and Applications · Management of metastatic bone disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Dipartimento di Scienze del Farmaco, Università degli Studi di Catania, viale A. Doria 6, Catania I-95125, Italy
References (49)
Show source-provided references
1. Basile, L., Pignatello, R., and Passirani, C. (2012). Active targeting strategies for anticancer drug nanocarriers. Curr. Drug Deliv., in press.10.2174/156720112800389089 ↗
2. The hallmark of cancer10.1016/S0092-8674(00)81683-9 ↗
3. Mechanisms of bone metastasis10.1056/NEJMra030831 ↗
4. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies10.1053/ctrv.2000.0210 ↗
5. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer10.1016/8756-3282(94)90703-X ↗
6. Scanning electron microscopy in bone pathology: Review of methods, potential and applications
7. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases10.1158/1078-0432.CCR-06-1007 ↗
8. The systemic treatment of bone metastases
9. Targeted and systemic radiotherapy in the treatment of bone metastasis10.1007/s10555-006-9025-z ↗
10. Exploiting the enhanced permeability and retention effect for tumor targeting10.1016/j.drudis.2006.07.005 ↗
11. Passive and active tumor targeting with nanocarriers10.2174/157016311796798991 ↗
12. Bone-specific drug delivery systems: Approaches via chemical modification of bone-seeking agents10.2165/00003088-200342150-00002 ↗
13. Bone-targeting macromolecular therapeutics10.1016/j.addr.2004.12.011 ↗
14. Kratz, F. (2011). Bisphosphonate-prodrugs. (Patent No. WO/2011/023367).
15. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones10.1016/8756-3282(96)00182-2 ↗
16. Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies10.1053/ctrv.2000.0210 ↗
17. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity10.1158/0008-5472.CAN-05-0264 ↗
18. Koul, H.K., Koul, S., and Meacham, R.B. (2012). New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer Prostatic Dis., in press.10.1038/pcan.2011.41 ↗
19. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein10.3109/10611869509015956 ↗
20. Wong, R.K.S., and Wiffen, P.J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev., 2.10.1002/14651858.CD002068 ↗
21. ‘Magic bullets’ for bone diseases: Progress in rational design of bone-seeking medicinal agents10.1039/B512310K ↗
22. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats10.1007/s002239900104 ↗
23. Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid10.1021/jm991109o ↗
24. Available online:http://www.mbcpharma.com/html/technology.html.
25. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages10.1016/j.biomaterials.2005.06.012 ↗
26. Development of a novel 99mTc-chelate conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent
27. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis10.1016/j.bmc.2008.09.010 ↗
28. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis10.1016/j.bmcl.2010.01.006 ↗
29. Synthesis of osteotropic hydroxybisphosphonate derivatives of fluoroquinolone antibacterials10.1016/j.ejmech.2011.10.049 ↗
30. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems10.1021/bc034090j ↗
31. Satchi-Fainaro, R., Miller, K., Shabat, D., and Erez, R. (2011). Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases. (20110142764), US Patent.
32. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate10.1002/anie.200805133 ↗
33. PLGA nanoparticles in drug delivery: The state of the art10.1615/CritRevTherDrugCarrierSyst.v21.i5.20 ↗
34. Available online:http://www.drugs.com/pro/alendronate.html.
35. DeRuiter, J., and Clark, R. Bisphosphonates: Calcium antiresorptive agents. Revision Spring 2002. Available online:http://www.duc.auburn.edu/~deruija/endo_bisphos.pdf.
36. A novel biomaterial for osteotropic drug nanocarriers. Synthesis and biocompatibility evaluation of a PLGA-alendronate conjugate10.2217/17435889.4.2.161 ↗
37. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate10.1016/j.biomaterials.2007.12.022 ↗
38. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases10.2174/156800910793605767 ↗
39. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone10.1016/j.jconrel.2007.06.003 ↗
40. Oberdorster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., Ausman, K., Carter, J., Karn, B., Kreyling, W., Lai, D., and The ILSI Research Foundation/Risk Science Institute Nanomaterial Toxicity Screening Working Group (2005). Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements for a screening strategy. Part. Fibre Toxicol., 2.10.1186/1743-8977-2-8 ↗
41. Borm, P.J.A., Robbins, D., Haubold, S., Kuhlbusch, T., Fissan, H., Donaldson, K., Schins, R., Stone, V., Kreyling, W., and Lademann, J. (2006). The potential risk of nanomaterials: A review carried out for ECETOC. Part. Fibre Toxicol., 3.10.1186/1743-8977-3-11 ↗
42. Cenni, E., Avnet, S., Granchi, D., Fotia, C., Salerno, M., Micieli, D., Sarpietro, M.G., Pignatello, R., Castelli, F., and Baldini, N. (2011). The effect of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate on human osteoclast precursors. J. Mat. Sci. Polym. Med., 7.10.1163/092050611X580373 ↗
43. Available online:http://www.drugs.com/pro/doxil.html.
44. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer10.1093/annonc/mdl484 ↗
45. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells
46. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery10.1096/fj.02-0088com ↗
47. Biodegradable nanoparticles for cytosolic delivery of therapeutics10.1016/j.addr.2007.06.003 ↗
48. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity10.1158/0008-5472.CAN-05-0264 ↗
49. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: A new role for these drugs?10.2174/157489206778776989 ↗